The Proclaimsm (Proleukin® Observational Study to Evaluate Treatment Patterns and Clinical Response in Malignancy) Study: The Response Rates for High Dose Interleukin-2 (HD IL-2) Therapy

被引：0
|
作者：
Kaufman, Howard [1 ]
McDermott, David [2 ]
Morse, Michael [3 ]
Lowder, James [4 ]
Wong, Michael [5 ]
机构：
[1] Rush Univ, Chicago, IL 60612 USA
[2] Harvard Univ, Boston, MA 02115 USA
[3] Duke Univ, Durham, NC USA
[4] Prometheus Labs Inc, San Diego, CA USA
[5] Univ So Calif, Los Angeles, CA USA
来源：
JOURNAL OF IMMUNOTHERAPY | 2012年 / 35卷 / 09期
关键词：
Interleukin-2; Immunotherapy;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：749 / 750
页数：2
相关论文
共 50 条
  • [41] Phase I study of prolonged low-dose subcutaneous recombinant interleukin-2 (IL-2) in patients with advanced cancer
    Angevin, E
    ValteauCouanet, D
    Farace, F
    Dietrich, PY
    Lecesne, A
    Triebel, F
    Escudier, B
    JOURNAL OF IMMUNOTHERAPY, 1995, 18 (03): : 188 - 195
  • [42] NCI 8628-A randomized phase II study of Ziv-aflibercept (Z) and high dose Interleukin-2 (IL-2) or IL-2 alone for inoperable stage III or IV melanoma
    Tarhini, Ahmad A.
    Frankel, Paul H.
    Ruel, Christopher
    Ernstoff, Marc S.
    Kuzel, Timothy M.
    Logan, Theodore F.
    Khushalani, Nikhil I.
    Tawbi, Hussein A.
    Margolin, Kim A.
    Awasthi, Sanjay
    McDermott, David F.
    Chen, Alice
    Lara, Primo N.
    Kirkwood, John M.
    CANCER RESEARCH, 2017, 77
  • [43] A Prospective Analysis of High-Dose Interleukin-2 (HD IL-2) following PD-1 inhibitor therapy in patients with metastatic melanoma and renal cell carcinoma.
    Buchbinder, Elizabeth Iannotti
    Dutcher, Janice P.
    Perritt, Jessica C.
    Clark, Joseph
    Holtan, Shernan G.
    Kirkwood, John M.
    Curti, Brendan D.
    Lao, Christopher D.
    Kaufman, Howard
    Fishman, Mayer N.
    McDermott, David F.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [44] A Pilot Study of Denileukin Diftitox (DD) in Combination With High-dose Interleukin-2 (IL-2) for Patients With Metastatic Renal Cell Carcinoma (RCC)
    Atchison, Elizabeth
    Eklund, John
    Martone, Brenda
    Wang, Lili
    Gidron, Adi
    Macvicar, Gary
    Rademaker, Alfred
    Goolsby, Charles
    Marszalek, Laura
    Kozlowski, James
    Smith, Norm
    Kuzel, Timothy M.
    JOURNAL OF IMMUNOTHERAPY, 2010, 33 (07) : 716 - 722
  • [45] Correlation of tumor programmed death ligand-1 (PD-L1) expression and response to treatment with high-dose interleukin-2 (HD IL-2) in clear cell metastatic renal cell carcinoma (ccmRCC).
    Crispin, Hilda
    Agarwal, Archana M.
    Salama, Mohamed E.
    Tantravahi, Srinivas Kiran
    Merriman, Joseph
    Straubhar, Alli M.
    Poole, Austin
    Nussenzvelg, Roberto
    Stenehjem, David I.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [46] Overall survival (OS) by clinical risk category for high dose interleukin-2 (HD IL-2) treated metastatic renal cell cancer (RCC): Data from PROCLAIM.
    Fishman, Mayer N.
    Clark, Joseph I.
    Alva, Ajjai Shivaram
    Curti, Brendan D.
    Agarwal, Neeraj
    Hauke, Ralph J.
    Mahoney, Kathleen Margaret
    Moon, Helen
    Treisman, Jonathan
    Tykodi, Scott
    Daniels, Gregory A.
    Morse, Michael
    Wong, Michael K. K.
    Kaufman, Howard
    Gregory, Nancy C.
    Dutcher, Janice P.
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [47] Intraprostatic interleukin-2 (IL-2) gene therapy: Results of a phase I clinical trial for the treatment of locally advanced prostate cancer
    Naitoh, J
    Gillespie, D
    Tso, CL
    Kaboo, R
    Stiles, A
    Figlin, R
    Belldegrun, A
    CANCER GENE THERAPY, 1998, 5 (06) : S1 - S1
  • [48] CLINICAL-RESPONSE TO INTERLEUKIN-2 (IL-2) LYMPHOKINE-ACTIVATED KILLER (LAK) THERAPY OF ADVANCED MELANOMA IN A HUMAN IMMUNODEFICIENCY VIRUS (HIV) POSITIVE PATIENT
    WALLACK, MK
    DAVILA, E
    RESNICK, L
    BUSSO, M
    GRONKA, S
    DARNELL, E
    BASH, JA
    JOURNAL OF BIOLOGICAL RESPONSE MODIFIERS, 1989, 8 (03): : 327 - 327
  • [49] Correlation of stable disease (SD) as best response with survival outcomes in patients (pts) with clear cell (cc) metastatic renal cell carcinoma (mRCC) treated with high-dose interleukin-2 (HD IL-2)
    Merriman, Joseph
    Parikh, Kinjal
    Tantravahi, Srinivas Kiran
    Straubhar, Alli M.
    Agarwal, Archana M.
    Sendilnathan, Arun
    Van Atta, Joan
    Batten, Julia A.
    Grossmann, Kenneth F.
    Samlowski, Wolfram E.
    Stenehjem, David D.
    Agarwal, Neeraj
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [50] Correlation of NRAS Mutations With Clinical Response to High-dose IL-2 in Patients With Advanced Melanoma
    Joseph, Richard W.
    Sullivan, Ryan J.
    Harrell, Robyn
    Stemke-Hale, Katherine
    Panka, David
    Manoukian, George
    Percy, Andrew
    Bassett, Roland L.
    Ng, Chaan S.
    Radvanyi, Laszlo
    Hwu, Patrick
    Atkins, Michael B.
    Davies, Michael A.
    JOURNAL OF IMMUNOTHERAPY, 2012, 35 (01) : 66 - 72
12345